EX-23.1 2 g084184_ex23-1.htm EXHIBIT 23.1

Exhibit 23.1



Independent Registered Public Accounting Firm’s Consent


We consent to the incorporation by reference in this Registration Statement of Chromocell Therapeutics Corporation on Form S-1 (Post-Effective Amendment No. 2) (File No. 333-269188) of our report dated April 16, 2024, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the financial statements of Chromocell Therapeutics Corporation as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 appearing in the Annual Report on Form 10-K of Chromocell Therapeutics Corporation for the year ended December 31, 2023. We also consent to the reference to our firm under the heading “Experts” in the Registration Statement.


Our report on the financial statements includes an emphasis of matter paragraph as to the preparation of the financial statements on a carve-out basis.


/s/ Marcum llp


Marcum llp

Houston, Texas

April 16, 2024